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This 2-year cross-sectional evaluation of nontuber-
culous mycobacterial (NTM) infections involved all Israeli 
medical centers that treat cystic ﬁ  brosis patients. The study 
comprised 186 patients whose sputum was analyzed for 
NTM. The prevalence of NTM isolates was 22.6%, and 
6.5% and 10.8% of the patients fulﬁ  lled the 1997 and 2007 
American Thoracic Society criteria for NTM lung disease, 
respectively.  Mycobacterium simiae (40.5%), M. absces-
sus (31.0%), and M. avium complex (14.3%) were the most 
prevalent. Presence of Aspergillus spp. in sputum and the 
number of sputum specimens processed for mycobacteria 
were the most signiﬁ   cant predictors for isolation of NTM 
(odds ratio [OR] = 5.14, 95% conﬁ  dence interval [CI] 1.87–
14.11 and OR = 1.47, 95% CI 1.17–1.85, respectively). The 
incidence of NTM pulmonary infections is increasing among 
cystic ﬁ  brosis patients, reﬂ  ecting the increase in longevity of 
such patients as well as environmental exposure to various 
species of mycobacteria.
T
he dramatic improvement in the survival of patients 
with cystic ﬁ  brosis (CF) has been complicated by the 
development of highly resistant strains of Pseudomonas 
aeruginosa and Staphylococcus aureus; the appearance 
of new virulent pathogens, such as Burkholderia cepacia; 
and the emergence of organisms of undetermined clinical 
importance, such as Alcaligenes xylosoxidans, Stenotroph-
omonas maltophilia, and the nontuberculous mycobacteria 
(NTM) (1–4). Since 1990, an increasing number of studies 
have reported the recovery of NTM from the respiratory 
tract of patients with CF at a prevalence of 2%–28% (2–
13); higher prevelances have been reported in the United 
States (14) than in Europe (4,11). Whether such ﬁ  ndings 
indicate infection or simply colonization of the airways by 
an environmental organism is not clear. The 1997 Ameri-
can Thoracic Society (ATS) guidelines for the diagnosis of 
NTM lung disease include compatible clinical and radio-
graphic ﬁ  ndings as well as bacteriologic ﬁ  ndings of 3 posi-
tive cultures or, alternatively, 2 positive cultures and a posi-
tive smear for acid-fast bacilli (AFB) (15). The 2007 ATS 
microbiologic criteria, however, require the following: 1) 2 
positive sputum cultures or 1 positive culture if it was ob-
tained through bronchial wash, lavage, or lung biopsy; or 2) 
>1 sputum or bronchial washings that are culture positive 
for NTM if mycobacterial histopathologic features were 
evident (16). In a recent multicenter study of CF patients 
in the United States, Olivier et al. (14) reported an over-
all prevalence of NTM in sputum of 13%. Most isolates 
in their study were of the Mycobacterium avium complex 
(MAC), although a high prevalence of M. abscessus was 
also noted. Only 20% of the samples met the 1997 ATS 
microbiologic criteria for disease. It was suggested that pa-
tients with CF and multiple positive NTM cultures, charac-
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teristic high-resolution computerized tomographic (HRCT) 
ﬁ   ndings, and progression of HRCT changes should be 
monitored closely and considered for antimycobacterial 
drug therapy (17).
In Israel, 468 patients with CF are currently treated in 
7 medical centers. Although all 7 report that they screen for 
NTM pulmonary secretions on a regular basis and during 
most CF exacerbations, we wanted to investigate the various 
approaches they used to diagnose NTM pulmonary disease. 
We also wanted to determine the prevalence of NTM infec-
tion, the different species involved, and the associated risk 
factors for the development of NTM pulmonary infections in 
Israeli patients whose sputum was processed for NTM.
Methods
Deﬁ  nition and Ascertainment of Cases
This retrospective observational study was conducted 
at all Israeli medical centers that treat patients with CF. The 
medical records of all CF patients from July 2001 through 
July 2003 were screened. The number of patients ranged 
from 15 to 134 per center, with a total of 468 patients. Most 
patients routinely visited the centers in intervals of at least 
3 months. The study population included CF patients >5 
years of age who had not undergone lung transplantation 
and in whom sputum specimens were processed for my-
cobacteria.
We deﬁ  ned NTM infection as a patient having had at 
least 1 positive isolate over time. NTM disease was deﬁ  ned 
as the condition in which a patient had a positive NTM iso-
late and met ATS disease criteria. CF patients who were 
evaluated at least once without evidence of NTM consti-
tuted the control group. We analyzed the data according to 
the 1997 and 2007 ATS criteria. The study was approved 
by the respective institutional review boards.
Data Collection and Study Design
The study design was cross-sectional. Demographic, 
clinical, and laboratory data for all eligible patients were 
collected from medical records, which included: age, gen-
der, CF genotype, sweat chloride level, body mass index, 
forced expiratory volume in 1 s (FEV1); average during the 
study period), pancreatic function, presence of hemoptysis, 
sputum cultures during the study period, length of hospi-
talization (total time throughout the study period), anti-
microbial agents administered (yes or no during the study 
period), and other treatment modalities.
Laboratory Methods
Respiratory tract specimens were assessed in the local 
microbiology laboratories of each center. The methods were 
not standardized, but the laboratories operated according 
to recommendations by international expert groups (18). 
When NTM did grow, however, isolates were forwarded 
to the National Mycobacterium Reference Laboratory of 
Israel for further identiﬁ  cation. Specimens were processed 
by standard methods and inoculated onto MB/BacT bottle 
(BacT/Alert System, bioMérieux, Marcy l’Etoile, France), 
a Lowenstein-Jensen slant, and a Middlebrook 7H11 selec-
tive agar plate (19–21). All inoculated media and broths 
were incubated at 36°C until growth was observed or up 
to 7 weeks. Direct smears and smears from colonies were 
stained with Ziehl-Neelsen stain. Species identiﬁ  cation was 
performed by conventional biochemical methods and by 
determining antimicrobial drug susceptibility patterns us-
ing the resistance ratio method and Etest (Biodisk, Solna, 
Sweden) (21,22). MAC isolates were conﬁ  rmed by using 
commercial RNA/DNA probes (Accuprobe, Gen-Probe, 
Inc., San Diego, CA, USA).
Data Analysis
Prevalence of NTM was calculated as the ratio be-
tween the number of CF patients with at least 1 positive 
culture and the total study population. Univariate analysis 
for the comparison of cases and controls was performed by 
using Student t test for continuous variables and the χ2 test 
for categorical variables. Multivariate logistic regression 
analysis was performed to evaluate the effect of predicting 
variables for NTM-positive cases. Only variables that were 
signiﬁ  cant in the univariate analyses (p<0.05) were includ-
ed in the model (age, number of sputum specimens that 
were processed for mycobacteria, number of hospitaliza-
tion days, number of days receiving antimicrobial agents, 
FEV1, presence of hemoptysis, growth of Pseudomonas or 
Aspergillus spp. in sputum, presence of allergic broncho-
pulmonary aspergillosis, and treatment with azithromycin 
or ibuprofen). Data were analyzed by using SAS Software, 
version 9.0 (Cary, NC, USA).
Results
Study Population
A total of 282 of the 468 eligible CF patients were 
excluded from the study: 203 did not have any sputum 
processed for mycobacteria, 59 were <5 years of age, 8 
underwent lung transplantation, 2 had received immuno-
suppressive treatments, and follow-up was not available for 
the remaining 10 (Table 1). Sputum specimens were pro-
cessed for mycobacteria for 265 (57%) patients. Four large 
centers (A, C, D, E, Table 1) evaluated 60%–80% of their 
CF patients for NTM, and 2 smaller centers (F, G, Table 1) 
evaluated 45% of their CF patients. One center (B, Table 1) 
did not evaluate its CF patients for NTM, and those patients 
were excluded from the study. 
For the patients whose sputum was processed for my-
cobacteria, the average number of sputum samples per pa-
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tient during the study period was 3.1 ± 3.03. Patients whose 
sputum was evaluated for NTM (n = 265) were older and 
had markers of the severe form of disease compared to 
those whose sputum was not evaluated for mycobacteria 
(n = 203) (Table 2). A total of 186 study participants were 
eventually enrolled in the study; 42 had NTM infection or 
disease and 144 were controls. Twelve of the patients with 
NTM infection had NTM disease according to the 1997 
ATS criteria; 20 patients had NTM disease according to the 
2007 ATS criteria (p = 0.07).
Prevalence of NTM
The prevalence of NTM isolation among CF pa-
tients was 22.6% (42/186) (95% conﬁ  dence interval [CI] 
16.2–27.9). The prevalence of NTM varied by geographic 
location: no NTM were isolated from patients residing in 
northern Israel (center E, Table 1), whereas the prevalence 
was 24%–29% in hospitals located in central and southern 
Israel (centers A, C, D, F, Table 1), (Figure).
According to 1997 ATS criteria, 12 patients (6.5%) 
had NTM disease; 7 (58.3%) of these had AFB on smear. 
According to the 2007 ATS criteria, 20 patients (10.8%) 
had NTM disease, of whom 8 (40.0%) had AFB on smear. 
The proportion of patients with NTM disease in centers A, 
C, and D was 7.3%, 12.9%, and 4.8%, respectively, accord-
ing to the 1997 ATS criteria, and 14.6%, 13.0% and 9.5%, 
respectively, according to the 2007 ATS criteria.
NTM Species
The most common mycobacterial species were M. simi-
ae (17 patients, 40.5%), M. abscessus (13 patients, 31.0%), 
and MAC (6 patients, 14.3%). M. fortuitum was isolated in 4 
patients (2 patients had both M. fortuitum and M. simiae, and 
1 patient had both M. fortuitum and M. abscessus). The spe-
cies of NTM could not be determined for 5 other patients.
Species distribution differed according to geographic 
location (Figure). M. simiae was the most prevalent in cen-
ter A, whereas M. abscessus was the most prevalent species 
in centers C and D. No mycobacteria were isolated in 2 
centers. Seven of the 12 patients with NTM disease accord-
ing to the 1997 ATS criteria were infected by M. simiae and 
4 by M. abscessus. The species could not be determined for 
1 patient. Nine of the 20 patients with NTM disease accord-
ing to the 2007 ATS criteria were infected by M. simiae, 7 
by M. abscessus, and 1 by MAC. The species could not be 
determined in 3 patients.
Case-Control Study
Patients with NTM were signiﬁ   cantly older (by 4.8 
years) than culture-negative study participants, had more 
sputum specimens processed for mycobacteria, had more ep-
isodes of hemoptysis (23.8% vs. 8.3%), a lower FEV1 (14.5 
L/s), a longer hospital stay (14.8 days), and more exposure 
to intravenous antimicrobial treatment (35.2 days) (Table 
3). Patients with NTM were treated with azithromycin and 
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Table 1. Number of patients in all medical centers and their reasons for exclusion from study 
Center Total no. patients  Absence of mycobacterial culture (%)  Age <5 y  Other causes*  No. patients included 
A 134 36 (27) 5 11 82
B 82 74 (90) 7 1 0
C 75 28 (37) 13 3 31
D 71 14 (20) 14 1 42
E 60 26 (43) 14 2 18
F3 1 1 7 ( 5 5 ) 4 2 8
G1 5 8 ( 5 4 ) 2 0 5
Total 468 203 (72)  59 (21%)  20 (7%)  186
*Other causes; lung transplantation, immunosuppressive therapy, dropped from follow-up. 
Table 2. Comparison of patients included in the current study, patients tested for NTM, and patients not tested for NTM* 
Parameter
Patients included in the 
current study (n = 186) 
Patients tested for 
NTM (n = 265) 
Patients not tested for 
NTM (n = 203)  p value 
Age (mean ± SD)  20.51 ± 10.40  20.22 ± 10.53  13.99 ± 10.70  0.0001 
Sex, F/M  74/112  105/160  86/117  0.54 
Hemoptysis 22  23  4  0.002 
FEV1, L/s (mean ± SD)  67.90 ± 22.09  65.18 ± 21.69  82.94 ± 16.20  0.0001 
Pancreatic insufficiency  135  151  131  0.09 
Hospitalization, d (mean ± SD)  21.77 ± 28.54  23.80 ± 32.44  8.44 ± 14.03  0.0001 
Administration of antimicrobial 
agents, d (mean ± SD) 
22.66 ± 47.51  19.98 ± 45.52  2.30 ± 10.28  0.0001 
 Azithromycin  104  114  51  0.001 
 Ibuprofen  7  15  6  0.16 
 Insulin  17  20  9  0.16 
 Systemic  steroids  13  37  19  0.12 
 Inhaled  steroids  96  106  105  0.01 
*NTM, nontuberculous mycobacteria; SD, standard deviation; FEV1, forced expiratory volume in 1 s. Nontuberculous Mycobacteria and Cystic Fibrosis
ibuprofen more frequently. They had higher rates of P. ae-
ruginosa (95.2% vs. 65.3% of controls) and Aspergillus spp. 
(66.7% vs. 21.5% of controls) in sputum samples. Both study 
and control groups were similar with respect to sex, sweat 
chloride level, pancreatic insufﬁ  ciency, and requirement for 
insulin and steroids. Culture-negative and culture-positive 
groups had similar frequencies of mild and severe genotypes 
and also had the same rates of S. aureus and S. maltophilia 
growth. A multivariate analysis demonstrated that the pres-
ence of Aspergillus spp. in sputum and the number of spu-
tum specimens processed for mycobacteria remained the 
only statistically signiﬁ  cant predictors for developing NTM 
infection (odds ratio [OR] 5.14, 95% CI 1.87–14.11 and OR 
1.47, 95% CI 1.17–1.85, respectively).
According to the 1997 ATS criteria, patients with NTM 
disease had more sputum specimens processed for myco-
bacteria, longer hospital stays, more courses of ibuprofen, 
higher isolation rate of Aspergillus spp., higher frequency 
of allergic bronchopulmonary aspergillosis, and more 
positive sputum smears than patients with NTM infection 
(Table 4). Analysis of the data according to the 2007 ATS 
criteria disclosed that patients with NTM disease had more 
sputum specimens processed for mycobacteria, used more 
inhaled steroids, and had more positive sputum smears. Pa-
tients with M. abscessus growth in sputum were younger 
than patients with the growth of other NTM (18.46 ± 6.42 
vs. 26.79 ± 11.63 years, p<0.05), tended to have positive 
smears (53.8% vs. 13.8%, p<0.001), and had frequent 
growth of S. maltophilia in sputum (15.4% vs. 0, p<0.05). 
Patients with M. simiae growth in sputum had worse sweat 
test results than those with the growth of other NTM (92.18 
± 45.42 vs. 60.08 ± 49.88, p<0.05); they had more episodes 
of hemoptysis (52.9% vs. 12.0%, p<0.05), and they were 
treated more often with inhaled steroids (82.3% vs. 48.0%, 
p<0.05) and systemic steroids (29% vs. 0, p<0.01).
Discussion
This multicenter study included 40% of the registered 
CF patients in Israel during a 2-year period and is the most 
representative study on NTM pulmonary infection among 
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Figure. Different species of nontuberculous mycobacteria isolated 
from patients with cystic ﬁ  brosis (unique patient isolate) in 4 medical 
centers. M., Mycobacterium.
Table 3. Comparison between patients and controls in univariate and multivariate analyses* 
Parameter Patients (n = 42)  Controls (n = 144)  p value  Adjusted OR  95% CI 
Age, y (mean ± SD)  24.2 ± 10.9 19.4 ± 10.0 0.014 1.03 0.99–1.09
Sex, F/M  18/24 56/88 0.64
No. sputum specimens (mean ± SD)  5.7 ± 4.8 2.4 ± 1.7 <0.0001 1.47 1.17–1.85
Hemoptysis 10 12 0.006 1.08 0.29–4.05
FEV1, L/s (mean ± SD)  56.7 ± 19.6 71.2 ± 21.8 0.0001 0.97 0.94–0.99
Pancreatic insufficiency  35 100 0.07
Sweat chloride, Meq/ L (mean ± SD) 73.1 ± 50.2 66.2 ± 48.3 0.43
Hospitalization, d (mean ± SD)  33.2 ± 37.5 18.4 ± 24.5 0.019 0.99 0.97–1.01
Administration of antimicrobial drugs, d 
(mean ± SD) 
49.9 ± 78.7 14.7 ± 29.4 0.007 0.99 0.98–1.00
Azithromycin treatment  30 74 0.02 1.00 0.99–1.00
Azithromycin  treatment, d (mean ± SD) 367.6 ± 302.7 221.9 ± 288.4 0.007 1.00 0.99–1.00
Ibuprofen treatment   5 2 0.001 4.72 0.60–36.85
Insulin treatment  4 13 0.92
Systemic steroids treatment  3 10 0.96
Inhaled steroids treatment  26 70 0.13
Pseudomonas aeruginosa 40 94 0.0005 0.76 0.32–1.79
Staphylococcus aureus 18 58 0.95
Aspergillus 28 31 <0.0001 5.14 1.87–14.11
Allergic bronchopulmonary aspergillosis  3 3 0.10
Haemophillus influenza 3 24 0.13
Alcaligenes xylosoxidans 0 5 0.22
Klebsiella pneumoniae 3 40 . 1 7
Stenotrophomonas maltophilia  2 3 0.34
*OR, odds ratio; CI, confidence interval; SD, standard deviation; FEV1, forced expiratory volume in 1 s. RESEARCH
CF patients thus far. The only other comparable published 
report was a multicenter study from the United States by 
Olivier et al. (14), in which only 10% of the CF popula-
tion was sampled. The overall prevalence of NTM in spu-
tum in the current study was 22.6%, higher than the 13% 
reported from the United States (14). Twenty-six percent 
of the culture-positive study participants had positive 
smears, and one third to half of patients met the 1997 and 
2007 ATS microbiologic criteria, respectively, for NTM 
disease. Half of the case-patients in our study had at least 
2 positive cultures in contrast to 29% among the US CF 
population. The high prevalence in this study reﬂ  ects the 
different mycobacterial ecology that exists in Israel. The 
ﬁ  ndings also may be related to the 2-year cross-sectional 
design of this study compared to point prevalence studies. 
Furthermore, our study included patients for whom their 
physician had a reason to obtain a mycobacterial culture. 
This may have preselected a population with a higher 
likelihood of having mycobacteria. The study by Olivier 
et al. (14), which reported a lower prevalence, enrolled 
patients and prospectively obtained 3 sputum specimens 
over the course of 1 year.
There was some variability in the frequency of these 
bacteria between different centers. This ﬁ  nding may be due 
to differences in the quality of microbiology laboratories, 
differences in antimicrobial drug treatment, or endemic oc-
currence of bacteria in certain centers.
In the present study, M. simiae was the most com-
mon species isolated (40.5%), followed by M. abscessus 
(31.0%) and MAC (14.3%). M. simiae was also isolated 
among half of the patients with NTM disease. In the US 
study, MAC and M. abscessus were isolated in 72% and 
16% of the cases, respectively. M. simiae is an infrequently 
found environmental organism that has rarely been associ-
ated with human disease. It has been reported as a cause 
of disseminated disease in AIDS patients (23–25) and the 
source of pulmonary disease in patients with underlying 
bronchiectatic lungs (26,27). To our knowledge, this is the 
ﬁ  rst report on M. simiae pulmonary disease in CF patients. 
M. simiae was also associated with an outbreak due to a 
contaminated hospital water supply, which was distributed 
from an aquifer (28). Interestingly, the medical center with 
the highest prevalence of M. simiae did have an aquifer as 
the primary water source. Repeated water surveys, howev-
er, did not ﬁ  nd contamination of facility water reservoirs as 
the source of the high prevalence of this species. M. simiae 
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Table 4. Comparison of patients with NTM infection and NTM disease according to 1997 and 2007 ATS criteria* 
1997 criteria  2007 criteria 
Parameter
NTM disease 
(n = 12) 
NTM infection 
(n = 30)  p value
NTM disease
(n = 20) 
NTM infection 
(n = 22)  p value 
Age, y (mean ± SD)  19.8 ± 9.1 26.0 ± 11.2 0.17 24.2 ± 11.7 24.3 ± 10.4 0.97
Sex, F/M  7/5 11/19 0.20 9/11 9/13 0.79
No. sputum specimens (mean ± SD) 9.0 ± 5.1 4.4 ± 4.0 0.01 8.0 ± 5.2 3.6 ± 3.2 0.003
BMI, kg/m
2 (mean ± SD)  18.9 ± 1.4 20.4 ± 4.0 0.19 19.7 ± 2.6 20.2 ± 4.1 0.63
Hemoptysis 4 6 0.36 6 4 0.37
FEV1, L/s (mean ± SD)  55.0 ± 23.0 57.4 ± 18.4 0.75 50.7 ± 20.3 62.1 ± 17.6 0.06
Pancreatic insufficiency  9 26 0.36 17 18 0.78
Sweat chloride (Meq/L) (mean ± SD)  66.5 ± 53.3 75.7 ± 49.6 0.61 81.9 ± 45.6 65.0 ± 53.7 0.28
Hospitalization, d (mean ± SD)  50.8 ± 52.5 26.2 ± 27.7 0.05 43.9 ± 44.1 23.6 ± 28.0 0.09
Administration of antimicrobial drug 
therapy, d (mean ± SD) 
87.8 ± 110.9 34.7 ± 57.1 0.14 70.1 ± 90.6 31.5 ± 62.7 0.12
Azithromycin 10 20 0.55 15 15 0.63
Azithromycin treatment, d (mean ± SD) 379.5 ± 258.6 362.9 ± 322.7 0.87 360.7 ± 297.5 374.0 ± 314.2 0.89
Ibuprofen 4 1 0.01 4 1 0.12
Insulin 1 3 0.87 2 2 0.92
Systemic steroids  2 1 0.13 2 1 0.49
Inhaled steroids  10 16 0.07 16 10 0.02
AFB in sputum  7 4 0.01 8 3 0.05
Pseudomonas aeruginosa 12 28 0.36 20 20 0.17
Staphylococcus aureus 7 11 0.2 8 10 0.72
Aspergillus spp. 11 17 0.03 16 12 0.12
Allergic bronchopulmonary aspergillosis  3 0 0.004 3 0 0.06
Hemophillus influenza 2 1 0.14 2 1 0.52
Klebsiella pneumoniae 1 2 0.85 2 1 0.55
Stenotrophomonas maltophilia  2 0 0.02 2 0 0.14
*NTM, nontuberculous mycobacteria; ATS, American Thoracic Society; SD, standard deviation; BMI, body mass index; FEV1, forced expiratory volume in 
1 s; AFB, acid-fast bacilli. Nontuberculous Mycobacteria and Cystic Fibrosis
seems to have a limited geographic distribution; most clini-
cal isolates have come from Arizona, New Mexico, Texas, 
Cuba, and Israel (29–31). In Israel, M. simiae is the most 
common NTM isolated from clinical specimens; the spe-
cies usually colonizes damaged lungs (30,31). The distri-
bution of M. simiae varied among treatment sites, with the 
highest incidence in central Israel (center A). In previous 
studies in Israel, ≈99% of M. simiae isolates were obtained 
from patients who resided on the coastal plain, mainly the 
Tel Aviv area (30).
As had been noted earlier by others (14), CF patients 
with NTM infection were older than those without NTM. 
In contrast to other studies, however, our CF patients with 
NTM infection had markers of severe disease, including 
lower FEV1, hemoptysis, higher frequency of P. aerugi-
nosa and Aspergillus spp. growth in sputum, longer hos-
pital stay, and higher exposure to intravenous antimicro-
bial agents, azithromycin, and ibuprofen. Mycobacterial 
colonization may be secondary to severe disease or that 
these mycobacteria cause the disease to be more severe. 
The association between NTM and markers of severe dis-
ease may be related to longer duration of disease or to the 
mycobacterial species involved. Severe disease could also 
promote altered mucociliary clearance, colonization, and 
infection with M. simiae and M. abscessus, while infection 
with MAC causes less progressive disease, mainly in older 
patients with mild disease (14).
In Olivier et al.’s study (14), P. aeruginosa was in-
versely associated with NTM, while the presence of S. au-
reus was positively associated with NTM. In our current 
study, patients with NTM tended to have less S. aureus and 
more P. aeruginosa in their lower airways. The strong as-
sociation between infection with NTM and Aspergillus spp. 
probably reﬂ  ects the severity of the disease. The presence 
of Aspergillus spp. or NTM may create favorable condi-
tions for the colonization and infections of each other.
Azithromycin has a potential immunomodulatory ef-
fect in the treatment of CF, mainly for chronic P. aeru-
ginosa respiratory tract infection (32). In our population, 
azithromycin was administered chieﬂ  y for its immunomod-
ulatory properties and not to treat NTM pulmonary disease. 
Our study patients with NTM were treated more often with 
azithromycin (71.5% of case-patients vs. 51.4% of con-
trols). Because macrolides are the treatment of choice for 
infections caused by MAC and M. abscessus, subtherapeu-
tic doses of macrolides can induce selection of macrolide-
resistant mycobacteria. The effect of long-term treatment 
with azithromycin on the antibimicrobial selection of NTM 
in CF patients remains undeﬁ  ned.
High doses of ibuprofen inhibit the inﬂ  ammatory re-
sponse to chronic infection, which contributes to lung 
destruction in patients with cystic ﬁ  brosis (33), and our 
patients with NTM were treated more frequently with ibu-
profen. Furthermore, prostaglandin E inhibitors up-regulate 
the Th1 function with increasing levels of tumor necrosis 
factor, γ-interferon, and interleukin-2, which are necessary 
for the control of mycobacterial infections (34). The effect 
of prostaglandin inhibitors on mycobacterial infection has 
not been assessed in depth.
We did not ﬁ  nd any correlation between the gene mu-
tation proﬁ  le and NTM infection. By contrast, others have 
demonstrated that 60.7% of patients with emerging bacteria 
were homozygous for the Delta F508 mutation in compari-
son to only 23.8% of the isolates from the control group (4).
Given the possibility that NTM may merely represent 
environmental contamination or simple colonization of the 
airways, we compared patients who were diagnosed as hav-
ing NTM pulmonary disease with those with NTM infec-
tion, and found that, according to both 1997 and 2007 ATS 
criteria, those with NTM disease had more sputum speci-
mens processed for mycobacteria and higher rates of posi-
tive smears. According to the 1997 criteria, patients with 
NTM disease had more severe pulmonary disease, and P. 
aeruginosa and Aspergillus spp. grew in their sputum more 
frequently.
The current high level of interest in NTM disease is 
the result of the recognition that NTM disease is encoun-
tered with increasing frequency in non-AIDS populations 
and in unrecognized settings with new manifestations. 
Furthermore, advances in mycobacteriology laboratories 
facilitated the publication of new diagnostic and therapeu-
tic guidelines (16). The percentage of patients in our study 
who meet the current criteria is higher than those who met 
the previous criteria. It should be noted, however, that these 
guidelines apply to patients with lung disease due to MAC, 
M. kansasii, and M. abscessus, and it is not certain that 
these diagnostic criteria are universally applicable for all 
NTM respiratory pathogens.
This study has several limitations. First, retrospective 
studies can be limited by ascertainment bias, despite our best 
efforts to review all available paper and electronic records. 
Second, although 6 of the 7 centers report that they screen 
for NTM pulmonary secretions on a regular basis and dur-
ing most exacerbations, only 45%–80% of patients in these 
centers were actually evaluated for the presence of NTM. 
Because testing for NTM was not routine in all centers, and 
since testing may have been performed preferentially on pa-
tients who showed clinical deterioration and in whom NTM-
related disease was suspected, our data may not precisely 
reﬂ  ect the overall prevalence of these bacteria in the popula-
tion. Furthermore, an average of 6 sputum specimens were 
analyzed during the study period for each study patient while 
only 2.4 specimens were analyzed for each control. Never-
theless, this survey did provide some interesting insights 
about how often CF physicians look for NTM in sputum and 
gives an overview of the Israeli experience.
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As the life expectancy of patients with CF increases 
and surveillance and microbiologic methods of detection 
improve, the prevalence of mycobacterial infection among 
the CF population appears to be increasing. The implica-
tion of this has not yet been conclusively established, and 
distinguishing between colonization and active disease re-
mains difﬁ  cult.
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